Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Kodiak Sciences (KOD) stock in plain English

Free brief · no signupStart here
KODPublished Nov 18, 2026
Kodiak Sciences Inc
Healthcare · Biotechnology
Develops antibody-biopolymer drug candidates to treat chronic retinal eye diseases like macular degeneration.
Assets:
ABC PlatformProprietary biopolymer conjugate chemistry engine
Tarcocimab tedemerLead retinal therapeutic candidate in Phase 3 clinical testing
Palo Alto headquartersLeased research laboratories and corporate offices
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

40
OPS ScoreOperating finances
Latest quote
+0.09%$97.90
$6.40B
n/a
-

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KOD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Kodiak Sciences (KOD) do?

Kodiak Sciences Inc (KOD) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops antibody-biopolymer drug candidates to treat chronic retinal eye diseases like macular degeneration. Builds biopolymer-conjugated therapies designed to extend how long retinal eye disease treatments remain active inside. It is worth $6.40B on the market.

Market cap
$6.40B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

KOD’s flags, in plain English

Each flag is a number from Kodiak Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 1.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 8.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Debt Is Driving

Heavy debt, 1166% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about KOD

How big is Kodiak Sciences?

Kodiak Sciences’ market cap is $6.40B: what all of its shares are worth together at today’s price.

What could go wrong with KOD?

The business generates no commercial sales and depends entirely on existing cash reserves to fund late-stage clinical trials. That is one risk on Kodiak Sciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Kodiak Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KOD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card